Hypoglycaemia in Clinical DiabetesSecond Edition
Other titles in the Wiley Diabetes in Practice SeriesExercise and Sport in Diabetes Second EditionEdited by Dinesh Nagi047...
Hypoglycaemia in Clinical DiabetesSecond EditionEdited byBrian M. FrierThe Royal Infirmary of Edinburgh, Scotland, UKMiles...
Copyright © 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,West Sussex PO19 8SQ, EnglandTelephone (+44)...
ToEmily, Ben and Marc
ContentsPreface ixContributors xi1 Normal Glucose Metabolism and Responses to Hypoglycaemia 1Ian A. Macdonald and Paromita...
viii CONTENTS13 Long-term Effects of Hypoglycaemia on Cognitive Function and theBrain in Diabetes 285Petros Perros and Ian...
PrefaceIn the second edition of this book, we have continued to emphasise the clinical significanceof hypoglycaemia to the...
ContributorsProfessor Stephanie A. Amiel, R.D. Lawrence Professor of Diabetes, Departmentof Medicine, King’s College Hospi...
xii CONTRIBUTORSDr Mark W.J. Strachan, Consultant Physician, Metabolic Unit, Western General Hospital,Crewe Road, Edinburg...
1 Normal Glucose Metabolismand Responses toHypoglycaemiaIan A. Macdonald and Paromita KingINTRODUCTIONControl of blood glu...
2 NORMAL GLUCOSE METABOLISM AND RESPONSESInsulin and glucagon are the two hormones controlling glucose homeostasis, and th...
NORMAL GLUCOSE HOMEOSTASIS 3Box 1.2 Actions of glucagonLiver↑ Glycogenolysis↑ Gluconeogenesis↑ Extraction of alanine↑ Keto...
4 NORMAL GLUCOSE METABOLISM AND RESPONSESAmino acidsFree FAGlycogenGlucoseGlycerolHepatic glucoseoutputFFA, TG,lipoprotein...
EFFECTS OF GLUCOSE DEPRIVATION 5Fed state (Figure 1.1b)In the fed state, in accordance with the rules of the metabolic gam...
6 NORMAL GLUCOSE METABOLISM AND RESPONSESIsotope techniques and Positron Emission Tomography (PET) allow the study ofmetab...
COUNTERREGULATION DURING HYPOGLYCAEMIA 7established whether this adaptation is of major benefit in protecting brain functi...
8 NORMAL GLUCOSE METABOLISM AND RESPONSESthat blood glucose starts to rise when plasma insulin concentrations are still te...
COUNTERREGULATION DURING HYPOGLYCAEMIA 9growth hormone are important only in prolonged hypoglycaemia. Therefore if glucago...
10 NORMAL GLUCOSE METABOLISM AND RESPONSESother studies in rats, led to the hypothesis that the ventromedial nucleus of th...
HORMONAL CHANGES DURING HYPOGLYCAEMIA 11Figure 1.5 Anatomy of the autonomic nervous system. Pre = preganglionic neurones; ...
12 NORMAL GLUCOSE METABOLISM AND RESPONSESFigure 1.6 (a) Muscle sympathetic activity during euglycaemia and hypoglycaemia....
HORMONAL CHANGES DURING HYPOGLYCAEMIA 13Neuroendocrine Activation (Box 1.3)Insulin-induced hypoglycaemia was used to study...
14 NORMAL GLUCOSE METABOLISM AND RESPONSESFigure 1.7 Anatomy of the hypothalamus and pituitary gland• ACTH: Secretion is g...
PHYSIOLOGICAL RESPONSES 15hormones. Vasopressin has glycolytic actions and oxytocin increases hepatic glucose outputin dog...
16 NORMAL GLUCOSE METABOLISM AND RESPONSESBox 1.4 Haemodynamic changes↑ Heart rate↑ Systolic blood pressure↑ Cardiac outpu...
PHYSIOLOGICAL RESPONSES 17Figure 1.8 Changes in regional blood flow during hypoglycaemiademonstrated a reduction in spleni...
18 NORMAL GLUCOSE METABOLISM AND RESPONSESblood flow during hypoglycaemia irrespective of skin blood flow. This change is ...
PHYSIOLOGICAL RESPONSES 19We do not have rights to reproduce thisfigure electronicallyFigure 1.9 Sudden onset of sweating,...
20 NORMAL GLUCOSE METABOLISM AND RESPONSEStemperature (Gale et al., 1983). In rats, mortality was increased in animals who...
REFERENCES 21NORMAL GLUCOSE HOMEOSTASISINSULIN : GLUCAGON RATIO(GH and CORTISOL)COUNTERREGULATIONRESTORE BLOODGLUCOSEADREN...
22 NORMAL GLUCOSE METABOLISM AND RESPONSESBearn AG, Bulling BH, Sherlock S (1952). The response of the liver to insulin in...
REFERENCES 23Hamilton-Wessler M, Bergman RN, Halter JB, Watanabe RM, Donovan CM (1994). The role ofliver glucosensors in t...
24 NORMAL GLUCOSE METABOLISM AND RESPONSESSokaloff (1989). Circulation and energy metabolism of the brain. In: Basic Neuro...
2 Symptoms of Hypoglycaemiaand Effects on MentalPerformance and EmotionsIan J. DearyINTRODUCTIONThis chapter describes the...
Table2.1CommonsymptomsassociatedwithhypoglycaemiaSymptomsassociatedwithhypoglycaemiaasderivedfrompopulationstudies(afterHe...
SYMPTOMS OF HYPOGLYCAEMIA 27appeared before others during hypoglycaemia; that the blood glucose level at which subjectsbec...
28 SYMPTOMS OF HYPOGLYCAEMIAThe Validity of Symptom BeliefsThe individuality of hypoglycaemic symptom clustersA great deal...
SYMPTOMS OF HYPOGLYCAEMIA 29aware of symptoms of hypoglycaemia is that they become alert to low and potentiallydangerous l...
30 SYMPTOMS OF HYPOGLYCAEMIAClassifying Symptoms of HypoglycaemiaUntil now the symptoms of hypoglycaemia have been treated...
SYMPTOMS OF HYPOGLYCAEMIA 31Table 2.2 Different authors’ lists of autonomic and neuroglycopenic symptoms of hypoglycaemiaA...
32 SYMPTOMS OF HYPOGLYCAEMIAduring the period of hypoglycaemia. Therefore, they would be especially aware of cognitiveshor...
SYMPTOMS OF HYPOGLYCAEMIA 33frequently reported symptoms of behavioural disturbance such as irritability, argumentative-ne...
34 SYMPTOMS OF HYPOGLYCAEMIAwithout the correct interpretation of the cause of the symptoms is equally dangerous. Further-...
SYMPTOMS OF HYPOGLYCAEMIA 35Figure 2.2 A model for the occurrence and avoidance of severe hypoglycaemia (after Gonder-Fred...
36 SYMPTOMS OF HYPOGLYCAEMIA• neuroglycopenic symptoms are as strongly related to actual blood glucose concentrationsas ar...
ACUTE HYPOGLYCAEMIA AND COGNITIVE FUNCTIONING 37In the midst of this ignorance, much hypoglycaemia may not be treated beca...
38 SYMPTOMS OF HYPOGLYCAEMIAThe hyperinsulinaemic glucose clamp technique allows more controlled experiments ofacute hypo-...
ACUTE HYPOGLYCAEMIA AND COGNITIVE FUNCTIONING 39Box 2.2 Cognitive function tests impaired during acute hypoglycaemia• Trai...
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Hypoglycaemia in clinical_diabetes
Upcoming SlideShare
Loading in...5
×

Hypoglycaemia in clinical_diabetes

4,006

Published on

Published in: Health & Medicine
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
4,006
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
190
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide

Hypoglycaemia in clinical_diabetes

  1. 1. Hypoglycaemia in Clinical DiabetesSecond Edition
  2. 2. Other titles in the Wiley Diabetes in Practice SeriesExercise and Sport in Diabetes Second EditionEdited by Dinesh Nagi047002206XComplementary Therapies and the Management of Diabetes and Vascular DiseaseEdited by Patricia Dunning047001458XDiabetes in Clinical Practice: Questions and Answers from Case StudiesN. Katsilambros, E. Diakoumopoulou, I. Ioannidis, S. Liatis, K. Makrilakis, N. Tentolouris and P. Tsapogas978 0470 035221Obesity and DiabetesEdited by Anthony Barnett and Sudhesh Kumar0470848987Prevention of Type 2 DiabetesEdited by Manfred Ganz0470857331Diabetes – Chronic Complications Second EditionEdited by Kenneth Shaw and Michael Cummings0470865972The Metabolic SyndromeEdited by Christopher Byrne and Sarah Wild0470025115Psychology in Diabetes Care Second EditionEdited by Frank J. Snoek and T. Chas Skinner0470023848The Foot in Diabetes Fourth EditionEdited by Andrew J.M. Boulton, Peter R. Cavanagh and Gerry Rayman0470015047Gastrointestinal Function in Diabetes MellitusEdited by Michael Horowitz and Melvin Samson047189916XDiabetic NephropathyEdited by Christoph Hasslacher0471489921Nutritional Management of Diabetes MellitusEdited by Gary Frost, Anne Dornhorst and Robert Moses0471497517Diabetes in Pregnancy: An International Approach to Diagnosis and ManagementEdited by Anne Dornhorst and David R. Hadden047196204X
  3. 3. Hypoglycaemia in Clinical DiabetesSecond EditionEdited byBrian M. FrierThe Royal Infirmary of Edinburgh, Scotland, UKMiles FisherGlasgow Royal Infirmary, Scotland, UK
  4. 4. Copyright © 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,West Sussex PO19 8SQ, EnglandTelephone (+44) 1243 779777Email (for orders and customer service enquiries): cs-books@wiley.co.ukVisit our Home Page on www.wiley.comAll Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted inany form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except underthe terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the CopyrightLicensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing ofthe Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & SonsLtd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed topermreq@wiley.co.uk, or faxed to (+44) 1243 770620.Designations used by companies to distinguish their products are often claimed as trademarks. All brand namesand product names used in this book are trade names, service marks, trademarks or registered trademarks of theirrespective owners. The Publisher is not associated with any product or vendor mentioned in this book.This publication is designed to provide accurate and authoritative information in regard to the subject mattercovered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. Ifprofessional advice or other expert assistance is required, the services of a competent professional should besought.Other Wiley Editorial OfficesJohn Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USAJossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USAWiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, GermanyJohn Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, AustraliaJohn Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809John Wiley & Sons Canada Ltd, 6045 Freemont Blvd, Mississauga, Ontario, L5R 4J3Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not beavailable in electronic books.Anniversary Logo Design: Richard J. PacificoLibrary of Congress Cataloging in Publication DataHypoglycaemia in clinical diabetes / edited by Brian M. Frier and Miles Fisher. — 2nd ed.p. ; cm.Includes bibliographical references and index.ISBN 978-0-470-01844-6 (cloth : alk. paper)1. Hypoglycemia. 2. Diabetes—Treatment—Complications. 3. Hypoglycemic agents—Sideeffects. I. Frier, Brian M. II. Fisher, Miles. III. Title: Hypoglycemia in clinical diabetes.[DNLM: 1. Hypoglycemia—complications. 2. Hypoglycemia—physiopathology. 3. DiabetesComplications. 4. Insulin—adverse effects. WK 880 H9963 2007]RC662.2.H965 2007616.4 66—dc222007012095British Library Cataloguing in Publication DataA catalogue record for this book is available from the British LibraryISBN 978-0-470-01844-6Typeset in 10/12pt Times by Integra Software Services Pvt. Ltd, Pondicherry, IndiaPrinted and bound in Great Britain by Antony Rowe Ltd, Chippenham, WiltshireThis book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least twotrees are planted for each one used for paper production.
  5. 5. ToEmily, Ben and Marc
  6. 6. ContentsPreface ixContributors xi1 Normal Glucose Metabolism and Responses to Hypoglycaemia 1Ian A. Macdonald and Paromita King2 Symptoms of Hypoglycaemia and Effects on Mental Performanceand Emotions 25Ian J. Deary3 Frequency, Causes and Risk Factors for Hypoglycaemia in Type 1Diabetes 49Mark W.J. Strachan4 Nocturnal Hypoglycaemia 83Simon R. Heller5 Moderators, Monitoring and Management of Hypoglycaemia 101Tristan Richardson and David Kerr6 Counterregulatory Deficiencies in Diabetes 121David Kerr and Tristan Richardson7 Impaired Awareness of Hypoglycaemia 141Brian M. Frier8 Risks of Strict Glycaemic Control 171Stephanie A. Amiel9 Hypoglycaemia in Children with Diabetes 191Krystyna A. Matyka10 Hypoglycaemia in Pregnancy 217Ann E. Gold and Donald W.M. Pearson11 Hypoglycaemia in Type 2 Diabetes and in Elderly People 239Nicola N. Zammitt and Brian M. Frier12 Mortality, Cardiovascular Morbidity and Possible Effects ofHypoglycaemia on Diabetic Complications 265Miles Fisher and Simon R. Heller
  7. 7. viii CONTENTS13 Long-term Effects of Hypoglycaemia on Cognitive Function and theBrain in Diabetes 285Petros Perros and Ian J. Deary14 Living with Hypoglycaemia 309Brian M. FrierIndex 333
  8. 8. PrefaceIn the second edition of this book, we have continued to emphasise the clinical significanceof hypoglycaemia to the person who has diabetes, particularly when receiving treatmentwith insulin. Since the first edition of the book was published in 1999, new therapies haveemerged, including new insulin analogues and inhaled insulin, and monitoring systems arenow available that can provide continuous recording of blood glucose. However, far fromminimising the risk of hypoglycaemia in clinical practice, the newer treatments have beenshown to be as liable to cause hypoglycaemia as before, while continuous blood glucosemonitoring has revealed that this side-effect of insulin therapy is even more common thanwas believed previously. The frequency of severe hypoglycaemia in vulnerable groups suchas children and elderly people receiving insulin therapy is unacceptably high, and presentspotentially serious risks to health as well as diminishing their quality of life. Much scientificresearch in recent years has focused on the effects of hypoglycaemia on the brain, providinga greater understanding of the protean effects of this metabolic abnormality. New data andconcepts have been incorporated in this edition, particularly where these are of importanceto clinical practice.In updating and revising this book about hypoglycaemia, particular emphasis has beengiven to the risk factors for hypoglycaemia and how these may be reduced or avoided. Newchapters have been included to discuss recognised moderators of hypoglycaemia and the roleof new glucose monitoring systems, to address the increasing problem of hypoglycaemia inpeople with type 2 diabetes and the elderly person, and to acknowledge the major importanceof nocturnal hypoglycaemia, which is frequently not identified in clinical practice but canhave serious consequences, not only in its immediate morbidity, but also in promoting thedevelopment of the acquired syndromes of hypoglycaemia.We are grateful for the expert assistance and support of the colleagues who havecontributed chapters, some of whom are new as authors for this edition. All have skillfullyhighlighted the relevance of the enhancement of scientific knowledge in this field to theeveryday management of diabetes, which we hope will assist all members of the diabetesteam in their efforts to prevent and manage the extremely common but unwanted scourgethat is hypoglycaemia.Brian M. FrierMiles Fisher
  9. 9. ContributorsProfessor Stephanie A. Amiel, R.D. Lawrence Professor of Diabetes, Departmentof Medicine, King’s College Hospital, Bessemer Road, London, SE5 9PJ (e-mail:stephanie.amiel@kcl.ac.uk)Professor Ian J. Deary, Department of Psychology, University of Edinburgh, 7 GeorgeSquare, Edinburgh, EH8 9JZ (e-mail: ian.deary@ed.ac.uk)Dr Miles Fisher, Consultant Physician, Glasgow Royal Infirmary, Glasgow, G4 0SF (e-mail:miles.fisher@northglasgow.scot.nhs.uk)Professor Brian M. Frier, Consultant Physician, Department of Diabetes, Royal Infirmary,51 Little France Crescent, Edinburgh, EH16 4SA (e-mail: brian.frier@luht.scot.nhs.uk)Dr Ann E. Gold, Consultant Physician, Wards 27 and 28, Aberdeen Royal Infirmary,Foresterhill, Aberdeen, AB25 2ZN (e-mail: ann.gold@nhs.net)Professor Simon R. Heller, Professor of Clinical Diabetes, Clinical Sciences Centre, Depart-ment of Diabetes & Endocrinology, Northern General Hospital, Herries Road, Sheffield, S57AU (e-mail: s.heller@sheffield.ac.uk)Dr David Kerr, Consultant Physician, The Royal Bournemouth Hospital, Castle Lane East,Bournemouth, BH7 7DW (e-mail: David.Kerr@rbch.nhs.uk)Dr Paromita King, Consultant Physician, Jenny O’Neill Diabetes Centre, Derbyshire RoyalInfirmary, London Road, Derby, DE1 2QY (e-mail: Paru.King@derbyhospitals.nhs.uk)Professor Ian A. Macdonald, Professor of Metabolic Physiology, Department of Physi-ology and Pharmacology, Medical School, Queen’s Medical Centre, Nottingham, NG7 2UH(e-mail: Ian.Macdonald@nottingham.ac.uk)Dr Krystyna A. Matyka, Senior Lecturer in Paediatrics, University of Warwick MedicalSchool, Division of Clinical Sciences, CSB Research Wing, UHCW Trust, Clifford BridgeRoad, Coventry, CV2 2DX (e-mail: K.A.Matyka@warwick.ac.uk)Dr Donald W.M. Pearson, Consultant Physician, Aberdeen Royal Infirmary, Foresterhill,Aberdeen, AB25 2ZN (e-mail: Dwm.Pearson@arh.grampian.scot.nhs.uk)Dr Petros Perros, Consultant Endocrinologist, Ward 15, Freeman Hospital, Freeman Road,Newcastle-Upon-Tyne, NE7 7DN (e-mail: Petros.Perros@ncl.ac.uk)Dr Tristan Richardson, Consultant Physician, Bournemouth Diabetes and EndocrineCentre, The Royal Bournemouth Hospital, Castle Lane East, Bournemouth, BH7 7DW(e-mail: Tristan.Richardson@rbch.nhs.uk)
  10. 10. xii CONTRIBUTORSDr Mark W.J. Strachan, Consultant Physician, Metabolic Unit, Western General Hospital,Crewe Road, Edinburgh, EH4 2XU (e-mail: mark.strachan@luht.scot.nhs.uk)Dr Nicola N. Zammitt, Specialist Registrar, Department of Diabetes, Royal Infirmaryof Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA (e-mail: nicolazam-mitt@hotmail.com)
  11. 11. 1 Normal Glucose Metabolismand Responses toHypoglycaemiaIan A. Macdonald and Paromita KingINTRODUCTIONControl of blood glucose is a fundamental feature of homeostasis, i.e., the process by whichthe internal environment of the body is maintained stable allowing optimal function. Bloodglucose concentrations are regulated within a narrow range (which in humans is known asnormoglycaemia or euglycaemia) despite wide variability in carbohydrate intake and physicalactivity. Teleologically, the upper limit is defended because high glucose concentrationscause microvascular complications, and the lower limit, because the brain cannot functionwithout an adequate supply of glucose. In this chapter the mechanisms that protect againsthypoglycaemia in healthy individuals and the physiological consequences of low glucoseconcentrations are discussed.NORMAL GLUCOSE HOMEOSTASISHumans evolved as hunter-gatherers and, unlike people today, did not consume regularmeals. Mechanisms therefore evolved for the body to store food when it was in abundance,and to use these stores to provide an adequate supply of energy, in particular in the form ofglucose when food was scarce. Cahill (1971) originally described the ‘rules of the metabolicgame’ which humans had to follow to ensure their survival. These rules were modified byTattersall (personal communication) and are as follows:1. Maintain glucose within very narrow limits.2. Maintain an emergency energy source (glycogen) which can be tapped quickly for fleeingor fighting.3. Waste not want not, i.e., store (fat and protein) in times of plenty.4. Use every trick in the book to maintain protein reserves.Hypoglycaemia in Clinical Diabetes, 2nd Edition. Edited by B.M. Frier and M. Fisher© 2007 John Wiley & Sons, Ltd
  12. 12. 2 NORMAL GLUCOSE METABOLISM AND RESPONSESInsulin and glucagon are the two hormones controlling glucose homeostasis, and thereforethe mechanisms enabling the ‘rules’ to be followed. The most important processes governedby these hormones are:• Glycogen synthesis and breakdown (glycogenolysis): Glycogen, a carbohydrate, is anenergy source stored in the liver and skeletal muscle. Liver glycogen is broken downto provide glucose for all tissues, whereas the breakdown of muscle glycogen results inlactate formation.• Gluconeogenesis: This is the production of glucose in the liver from precursors: glycerol,lactate and amino acids (in particular alanine). The process can also occur in the kidneys,but this site is not important under physiological conditions.• Glucose uptake and metabolism (glycolysis) by skeletal muscle and adipose tissue.The actions of insulin and glucagon are summarised in Boxes 1.1 and 1.2. Insulin is ananabolic hormone, reducing glucose output by the liver (hepatic glucose output), increasingthe uptake of glucose by muscle and adipose tissue (increasing peripheral uptake) andincreasing protein and fat formation. Glucagon opposes the actions of insulin in the liver.Thus insulin tends to reduce, and glucagon to increase, blood glucose concentrations.Box 1.1 Actions of insulinLiver↑ Glycogen synthesis (↑ glycogen synthetase activity)↑ Glycolysis↑ Lipid formation↑ Protein formation↓ Glycogenolysis (↓ phosphorylase activity)↓ Gluconeogenesis↓ Ketone formationMuscle↑ Uptake of glucoseamino acidsketonepotassium↑ Glycolysis↑ Synthesis of glycogenprotein↓ Protein catabolism↓ Release of amino acidsAdipose tissue↑ Uptake glucosepotassiumStorage of triglyceride
  13. 13. NORMAL GLUCOSE HOMEOSTASIS 3Box 1.2 Actions of glucagonLiver↑ Glycogenolysis↑ Gluconeogenesis↑ Extraction of alanine↑ KetogenesisNo significant peripheral actionThe metabolic effects of insulin and glucagon and their relationship to glucose homeostasisare best considered in relationship to fasting and the postprandial state (Siegal and Kreisberg,1975). In both these situations it is the relative and not absolute concentrations of thesehormones that are important.Fasting (Figure 1.1a)During fasting, insulin concentrations are reduced and glucagon increased, which main-tains blood glucose concentrations in accordance with rule 1 above. The net effect is toreduce peripheral glucose utilisation, to increase hepatic glucose production and to providenon-glucose fuels for tissues not entirely dependent on glucose. After a short (for exampleovernight) fast, glucose production needs to be 5–6 g/h to maintain blood glucose concen-trations, with the brain using 80% of this. Glycogenolysis provides 60–80% and gluconeo-genesis 20–40% of the required glucose. In prolonged fasts, glycogen becomes depletedand glucose production is primarily from gluconeogenesis, with an increasing proportionfrom the kidney compared to the liver. In extreme situations renal gluconeogenesis cancontribute as much as 45% of glucose production. Thus glycogen is the short term or ‘emer-gency’ fuel source (rule 2), with gluconeogenesis predominating during more prolongedfasts. The following metabolic alterations enable this increase in glucose productionto occur:• Muscle: Glucose uptake and oxidative metabolism are reduced and fatty acid oxidationincreased. Amino acids are released.• Adipose tissue: There are reductions in glucose uptake and triglyceride storage. Theincrease in the activity of the enzyme hormone-sensitive lipase results in hydrolysisof triglyceride to glycerol (a gluconeogenic precursor) and fatty acids, which can bemetabolised.• Liver: Increased cAMP concentrations result in increased glycogenolysis and gluconeo-genesis thus increasing hepatic glucose output. The uptake of gluconeogenic precursors(i.e. amino acids, glycerol, lactate and pyruvate) is also increased. Ketone bodies areproduced in the liver from fatty acids. This process is normally inhibited by insulin andstimulated by glucagon, thus the hormonal changes during fasting lead to an increase inketone production. Fatty acids are also a metabolic fuel used by the liver and provide asource of energy for the reactions involved in gluconeogenesis.
  14. 14. 4 NORMAL GLUCOSE METABOLISM AND RESPONSESAmino acidsFree FAGlycogenGlucoseGlycerolHepatic glucoseoutputFFA, TG,lipoproteinKetonesMuscleGlucoseFree FATriglycerideAdipose TissueGlycogenGlucoseGlycerolHepatic glucoseoutputFFA, TG,LiverFASTING POST PRANDIALTGFA GlycerolphosphateFA GlycerolphosphateGlycerol TriglycerideKetonesglucagon, insulin Insulin, glucagonlactate GlycogenProteinAmino acids ProteinGlucose GlycogenlactateAmino acidsFAFA(a) (b)Figure 1.1 Metabolic pathways for glucose homeostasis in muscle, adipose tissue and liver duringfasting (left) and postprandially (right). FA = fatty acids; TG = triglyceride (associated CO2 productionexcluded for clarity)The reduced insulin : glucagon ratio favours a catabolic state, but the effect on fatmetabolism is greater than protein, and thus muscle is relatively preserved (rule 4). Theseadaptations meant that not only did hunter-gatherers have sufficient muscle power topursue their next meal, but also that brain function was optimally maintained to help themdo this.
  15. 15. EFFECTS OF GLUCOSE DEPRIVATION 5Fed state (Figure 1.1b)In the fed state, in accordance with the rules of the metabolic game, excess food is stored asglycogen, protein and fat (rule 3). The rise in glucose concentrations results in an increasein insulin and reduction in glucagon secretion. This balance favours glucose utilisation,reduction of glucose production and increases glycogen, triglyceride and protein formation.The following changes enable these processes to occur:• Muscle: Insulin increases glucose transport, oxidative metabolism and glycogen synthesis.Amino acid release is inhibited and protein synthesis is increased.• Adipose tissue: In the fat cells, glucose transport is increased, while lipolysis is inhibited.At the same time the enzyme lipoprotein lipase, located in the capillaries, is activatedand causes triglyceride to be broken down to fatty acids and glycerol. The fatty acidsare taken up into the fat cells and re-esterified to triglyceride (using glycerol phosphatederived from glucose) before being stored.• Liver: Glucose uptake is increased in proportion to plasma glucose, a process which doesnot need insulin. However, insulin does decrease cAMP concentrations, which results in anincrease in glycogen synthesis and the inhibition of glycogenolysis and gluconeogenesis.These effects ‘retain’ glucose in the liver and reduce hepatic glucose output.This complex interplay between insulin and glucagon maintains euglycaemia and enablesthe rules of the metabolic game to be followed, ensuring not only the survival of thehunter-gatherer, but also of modern humans.EFFECTS OF GLUCOSE DEPRIVATION ON CENTRAL NERVOUSSYSTEM METABOLISMThe brain constitutes only 2% of body weight, but consumes 20% of the body’s oxygenand receives 15% of its cardiac output (Sokaloff, 1989). It is almost totally dependenton carbohydrate as a fuel and since it cannot store or synthesise glucose, depends ona continuous supply from circulating blood. The brain contains the enzymes needed tometabolise fuels other than glucose such as lactate, ketones and amino acids, but underphysiological conditions their use is limited by insufficient quantities in the blood or slowrates of transport across the blood-brain barrier. When arterial blood glucose falls below3 mmol/l, cerebral metabolism and function decline.Metabolism of glucose by the brain releases energy, and also generates neurotransmitterssuch as gamma amino butyric acid (GABA) and acetylcholine, together with phospholipidsneeded for cell membrane synthesis. When blood glucose concentration falls, changes inthe synthesis of these products may occur within minutes because of reduced glucosemetabolism, which can alter cerebral function. This is likely to be a factor in producingthe subtle changes in cerebral function detectable at blood glucose concentrations as highas 3 mmol/l, which is not sufficiently low to cause a major depletion in ATP or creatinephosphate, the brain’s two main sources of energy (McCall, 1993).
  16. 16. 6 NORMAL GLUCOSE METABOLISM AND RESPONSESIsotope techniques and Positron Emission Tomography (PET) allow the study ofmetabolism in different parts of the brain and show regional variations in metabolismduring hypoglycaemia. The neocortex, hippocampus, hypothalamus and cerebellum are mostsensitive to hypoglycaemia, whereas metabolism is relatively preserved in the thalamusand brainstem. Changes in cerebral function are initially reversible, but during prolongedsevere hypoglycaemia, general energy failure (due to the depletion of ATP and creatinephosphate) can cause permanent cerebral damage. Pathologically this is caused by selectiveneuronal necrosis most likely due to ‘excitotoxin’ damage. Local energy failure induces theintrasynaptic release of glutamate or aspartate, and failure of reuptake of the neurotrans-mitters increases their concentrations. This leads to the activation of N-methyl-D-aspartate(NMDA) receptors causing cerebral damage. One study in rats has shown that an experi-mental compound called AP7, which blocks the NMDA receptor, can prevent 90% of thecerebral damage associated with severe hypoglycaemia (Wieloch, 1985). In humans withfatal hypoglycaemia, protracted neuroglycopenia causes laminar necrosis in the cerebralcortex and diffuse demyelination. Regional differences in neuronal necrosis are seen, withthe basal ganglia and hippocampus being sensitive, but the hypothalamus and cerebellumbeing relatively spared (Auer and Siesjö, 1988; Sieber and Traysman, 1992).The brain is very sensitive to acute hypoglycaemia, but can adapt to chronic fuel depri-vation. For example, during starvation, it can metabolise ketones for up to 60% of itsenergy requirements (Owen et al., 1967). Glucose transport can also be increased in theface of hypoglycaemia. Normally, glucose is transported into tissues using proteins calledglucose transporters (GLUT) (Bell et al., 1990). This transport occurs down a concentrationgradient faster than it would by simple diffusion and does not require energy (facilitateddiffusion). There are several of these transporters, with GLUT 1 being responsible fortransporting glucose across the blood-brain barrier and GLUT 3 for transporting glucoseinto neurones (Figure 1.2). Chronic hypoglycaemia in animals (McCall et al., 1986) andin humans (Boyle et al., 1995) increases cerebral glucose uptake, which is thought to bepromoted by an increase in the production and action of GLUT 1 protein. It has not beenFigure 1.2 Transport of glucose into the brain across the blood–brain barrier
  17. 17. COUNTERREGULATION DURING HYPOGLYCAEMIA 7established whether this adaptation is of major benefit in protecting brain function duringhypoglycaemia.COUNTERREGULATION DURING HYPOGLYCAEMIAThe potentially serious effects of hypoglycaemia on cerebral function mean that not onlyare stable blood glucose concentrations maintained under physiological conditions, but alsoif hypoglycaemia occurs, mechanisms have developed to combat it. In clinical practice, theprincipal causes of hypoglycaemia are iatrogenic (as side-effects of insulin and sulphony-lureas used to treat diabetes) and excessive alcohol consumption. Insulin secreting tumours(such as insulinoma) are rare. The mechanisms that correct hypoglycaemia are called coun-terregulation, because the hormones involved oppose the action of insulin and therefore arethe counterregulatory hormones. The processes of counterregulation were identified in themid 1970s and early 1980s, using either a bolus injection or continuous infusion of insulinto induce hypoglycaemia (Cryer, 1981; Gerich, 1988). The response to the bolus injectionof 0.1 U/kg insulin in a normal subject is shown in Figure 1.3. Blood glucose concentrationsdecline within minutes of the administration of insulin and reach a nadir after 20–30 minutes,then gradually rise to near normal by two hours after the insulin was administered. The factFigure 1.3 (a) Glucose and (b) insulin concentrations after intravenous injection of insulin 0.1 U/kgat time 0. Reproduced from Garber et al. (1976) by permission of the Journal of Clinical Investigation
  18. 18. 8 NORMAL GLUCOSE METABOLISM AND RESPONSESthat blood glucose starts to rise when plasma insulin concentrations are still ten times thebaseline values means that it is not simply the reduction in insulin that reverses hypogly-caemia, but active counterregulation must also occur. Many hormones are released whenblood glucose is lowered (see below), but glucagon, the catecholamines, growth hormoneand cortisol are regarded as being the most important.Several studies have determined the relative importance of these hormones by producingisolated deficiencies of each hormone (by blocking its release or action) and assessingthe subsequent response to administration of insulin. These studies are exemplified inFigure 1.4 which assesses the relative importance of glucagon, adrenaline (epinephrine) andgrowth hormone in the counterregulation of short term hypoglycaemia. Somatostatin infusionblocks glucagon and growth hormone secretion and significantly impairs glucose recovery(Figure 1.4a). If growth hormone is replaced in the same model to produce isolated glucagondeficiency (Figure 1.4b), and glucagon replaced to produce isolated growth hormone defi-ciency (Figure 1.4c), it is clear that it is glucagon and not growth hormone that is responsiblefor acute counterregulation. Combined alpha and beta adrenoceptor blockade using phento-lamine and propranolol infusions or adrenalectomy (Figure 1.4d), can be used to evaluatethe role of the catecholamines. These and other studies demonstrate that glucagon is themost important counterregulatory hormone whereas catecholamines provide a backup ifglucagon is deficient (for example in type 1 diabetes, see Chapters 6 and 7). Cortisol andFigure 1.4 Glucose recovery from acute hypoglycaemia. Glucose concentration following an intra-venous injection of insulin of 0.05 U/kg at time 0; after (a) saline infusion (continuous line) andsomatostatin, (b) somatostatin and growth hormone (GH), (c) somatostatin and glucagon, (d) combinedalpha and beta blockade with phentolamine and propranolol infusions or adrenalectomy, (e) somato-statin with alpha and beta blockade, and (f) somatostatin in adrenalectomised patients. Saline infu-sion = continuous lines; experimental study = broken lines. Reproduced from Cryer (1981) courtesyof the American Diabetes Association (epinephrine = adrenaline)
  19. 19. COUNTERREGULATION DURING HYPOGLYCAEMIA 9growth hormone are important only in prolonged hypoglycaemia. Therefore if glucagonand catecholamines are both deficient, as in longstanding type 1 diabetes, counterregulationis seriously compromised, and the individual is defenceless against acute hypoglycaemia(Cryer, 1981).Glucagon and catecholamines increase glycogenolysis and stimulate gluconeogenesis.Catecholamines also reduce glucose utilisation peripherally and inhibit insulin secretion.Cortisol and growth hormone increase gluconeogenesis and reduce glucose utilisation. Therole of the other hormones (see below) in counterregulation is unclear, but they are unlikelyto make a significant contribution. Finally, there is evidence that during profound hypo-glycaemia (blood glucose below 1.7 mmol/l), hepatic glucose output is stimulated directly,although the mechanism is unknown. This is termed hepatic autoregulation.The depth, as well as the duration, of hypoglycaemia is important in determining themagnitude of the counterregulatory hormone response. Studies using ‘hyperinsulinaemicclamps’ show a hierarchical response of hormone production. In this technique, insulin isinfused at a constant rate and a glucose infusion rate varied to maintain blood glucoseconcentrations within ±0 2mmol/l of target concentrations. This permits the controlledevaluation of the counterregulatory hormone response at varying degrees of hypoglycaemia.It also demonstrates that glucagon, catecholamines and growth hormone start to be secretedat a blood glucose concentration of 3.5–3.7 mmol/l, with cortisol produced at a lower glucoseof 3.0 mmol/l (Mitrakou et al., 1991). The counterregulatory response is initiated beforeimpairment in cerebral function commences, usually at a blood glucose concentration ofapproximately 3.0 mmol/l (Heller and Macdonald, 1996).The magnitude of the hormonal response also depends on the length of the hypogly-caemic episode. The counterregulatory hormonal response commences up to 20 minutesafter hypoglycaemia is achieved and continues to rise for 60 minutes (Kerr et al., 1989).In contrast, this response is attenuated as a result of a previous episode of hypoglycaemia(within a few days) (reviewed by Heller and Macdonald, 1996) and even by prolongedexercise the day before hypoglycaemia is induced. Galassetti et al. (2001) showed that innon-diabetic subjects three hours of moderate intensity exercise the previous day markedlydecreased the counterregulatory response to hypoglycaemia induced by the infusion ofinsulin, and that the reduced counterregulatory response was more marked in men thanin women.Although the primary role of the counterregulatory hormones is on glucose metabolism,any effects on fatty acid utilisation can have an indirect effect on blood glucose. Thus,the increase in plasma epinephrine (adrenaline) (and activation of the sympathetic nervoussystem) that is seen in hypoglycaemia can stimulate lipolysis of triglyceride in adipose tissueand muscle and release fatty acids which can be used as an alternative fuel to glucose, makingmore glucose available for the CNS. Enoksson et al. (2003) demonstrated that patients withtype 1 diabetes, who had lower plasma epinephrine responses to hypoglycaemia than non-diabetic controls, also had reduced rates of lipolysis in adipose tissue and skeletal muscle,making them more dependent on glucose as a fuel and therefore at risk of developing a moresevere hypoglycaemia.The complex counterregulatory and homeostatic mechanisms described above are thoughtto be mostly under the control of the central nervous system. Evidence for this comesfrom studies in dogs, where glucose was infused into the carotid and vertebral arteries tomaintain euglycaemia in the brain. Despite peripheral hypoglycaemia, glucagon did notincrease and responses of the other counterregulatory hormones were blunted. This, and
  20. 20. 10 NORMAL GLUCOSE METABOLISM AND RESPONSESother studies in rats, led to the hypothesis that the ventromedial nucleus of the hypothalamus(VMH), which does not have a blood–brain barrier, acts as a glucose-sensor and co-ordinatescounterregulation (Borg et al., 1997). However, evidence exists that other parts of the brainmay also be involved in mediating counterregulation.It is now clear that glucose-sensing neurones can involve either glucokinase or ATP-sensitive K+channels (Levin et al., 2004). In rats, the VMH has ATP-sensitive K+channelswhich seem to be involved in the counterregulatory responses to hypoglycaemia, as injectionof the sulphonylurea, glibenclamide, directly into the VMH suppressed hormonal responsesto systemic hypoglycaemia (Evans et al., 2004).The existence of hepatic autoregulation suggests that some peripheral control should exist.Studies producing central euglycaemia and hepatic portal venous hypoglycaemia in dogshave provided evidence for hepatic glucose sensors and suggest that these sensors, as wellas those in the brain, are important in the regulation of glucose (Hamilton-Wessler et al.,1994). However, this topic is somewhat controversial and more recent studies on dogs havefailed to demonstrate an effect of hepatic sensory nerves on the responses to hypoglycaemia(Jackson et al., 2000). Moreover, studies in humans by Heptulla et al. (2001) showedthat providing glucose orally rather than intravenously during a hypoglycaemic hyperin-sulinaemic clamp actually enhanced the counterregulatory hormone responses rather thanreduced them.HORMONAL CHANGES DURING HYPOGLYCAEMIAHypoglycaemia induces the secretion of various hormones, some of which are responsible forcounterregulation, many of the physiological changes that occur as a consequence of loweringblood glucose and contribute to symptom generation (see Chapter 2), The stimulation of theautonomic nervous system is central to many of these changes.Activation of the Autonomic Nervous SystemThe autonomic nervous system comprises sympathetic and parasympathetic components(Figure 1.5). Fibres from the sympathetic division leave the spinal cord with the ventral rootsfrom the first thoracic to the third or fourth lumbar nerves to synapse in the sympatheticchain or visceral ganglia, and the long postganglionic fibres are incorporated in somaticnerves. The parasympathetic pathways originate in the nuclei of cranial nerves III, VII, IXand X, and travel with the vagus nerve. A second component, the sacral outflow, suppliesthe pelvic viscera via the pelvic branches of the second to fourth spinal nerves. The gangliain both cases are located near the organs supplied, and the postganglionic neurones aretherefore short.Selective activation of both components of the autonomic system occurs during hypo-glycaemia. The sympathetic nervous system in particular is responsible for many of thephysiological changes during hypoglycaemia and the evidence for its activation can beobtained indirectly by observing functional changes such as cardiovascular responses (consid-ered below), measuring plasma catecholamines which gives a general index of sympatheticactivation, or by directly recording sympathetic activity.
  21. 21. HORMONAL CHANGES DURING HYPOGLYCAEMIA 11Figure 1.5 Anatomy of the autonomic nervous system. Pre = preganglionic neurones; post = post-ganglionic neurones; RC = ramus communicansDirect recordings are possible from sympathetic nerves supplying skeletal muscle and skin.Sympathetic neural activity in skeletal muscle involves vasoconstrictor fibres which innervateblood vessels and are involved in controlling blood pressure. During hypoglycaemia (inducedby insulin), the frequency and amplitude of muscle sympathetic activity are increased asblood glucose falls, with an increase in activity eight minutes after insulin is injectedintravenously, peaking at 25–30 minutes coincident with the glucose nadir, and persisting
  22. 22. 12 NORMAL GLUCOSE METABOLISM AND RESPONSESFigure 1.6 (a) Muscle sympathetic activity during euglycaemia and hypoglycaemia. Reproducedfrom Fagius et al. (1986) courtesy of the American Diabetes Association. (b) Skin sympatheticactivity during euglycaemia and hypoglycaemia. Reproduced from Berne and Fagius (1986), with kindpermission from Springer Science and Business Mediafor 90 minutes after euglycaemia is restored (Figure 1.6a) (Fagius et al., 1986). Duringhypoglycaemia, a sudden increase in skin sympathetic activity is seen, which coincideswith the onset of sweating. This sweating leads to vasodilatation of skin blood vessels,which is also contributed to by a reduction in sympathetic stimulation of the vasoconstrictorcomponents of skin arterio-venous anastomoses (Figure 1.6b) (Berne and Fagius, 1986).These effects (at least initially) increase total skin blood flow and promote heat loss fromthe body.Activation of both muscle and skin sympathetic nerve activity are thought to be centrallymediated. Tissue neuroglycopenia can be produced by 2-deoxy-D-glucose, a glucoseanalogue, without increasing insulin. Infusion of this analogue causes stimulation of muscleand skin sympathetic activity demonstrating that it is the hypoglycaemia per se, and not theinsulin used to induce it, which is responsible for the sympathetic activation (Fagius andBerne, 1989).The activation of the parasympathetic nervous system (vagus nerve) during hypoglycaemiacannot be measured directly. The most useful index of parasympathetic function is themeasurement of plasma pancreatic polypeptide, the peptide hormone secreted by the PP cellsof the pancreas, which is released in response to vagal stimulation.
  23. 23. HORMONAL CHANGES DURING HYPOGLYCAEMIA 13Neuroendocrine Activation (Box 1.3)Insulin-induced hypoglycaemia was used to study pituitary function as early as the 1940s.The development of assays for adrenocorticotrophic hormone (ACTH) and growth hormone(GH) allowed the direct measurement of pituitary function during hypoglycaemia in the1960s, and many of the processes governing these changes were unravelled before eluci-dation of the counterregulatory system. The studies are comparable to those evaluatingcounterregulation, in that potential regulatory factors are blocked to measure the hormonalresponse to hypoglycaemia with and without the regulating factor.Box 1.3 Neuroendocrine activationHypothalamus ↑ Corticotrophic releasing hormone↑ Growth hormone releasing hormoneAnterior Pituitary ↑ Adrenocorticotrophic hormone↑ Beta endorphin↑ Growth hormone↑ Prolactin↔ Thyrotrophin↔ GonadotrophinsPosterior pituitary ↑ Vasopressin↑ OxytocinPancreas ↑ Glucagon↑ Pancreatic polypeptide↑ InsulinAdrenal ↑ Cortisol↑ Epinephrine (adrenaline)↑ AldosteroneOthers ↑ Parathyroid hormone↑ Gastrin↑ Somatostatin (28)Hypothalamus and anterior pituitaryACTH, GH and prolactin concentrations increase during hypoglycaemia, but there is nochange in thyrotrophin or gonadotrophin secretion. The secretion of these pituitary hormonesis controlled by releasing factors which are produced in the median eminence of the hypotha-lamus, secreted into the hypophyseal portal vessels and then pass to the pituitary gland(Figure 1.7). The mechanisms regulating the releasing factors are incompletely understood,but may involve the ventromedial nucleus, one site where brain glucose sensors are situated(Fish et al., 1986).
  24. 24. 14 NORMAL GLUCOSE METABOLISM AND RESPONSESFigure 1.7 Anatomy of the hypothalamus and pituitary gland• ACTH: Secretion is governed by release of corticotrophin releasing hormone (CRH) fromthe hypothalamus; alpha adrenoceptors stimulate CRH release, and beta adrenoceptorshave an inhibitory action. A variety of neurotransmitters control the release of CRH intothe portal vessels, including serotonin and acetylcholine which are stimulatory and GABAwhich is inhibitory. The increase in ACTH causes cortisol to be secreted from the corticesof the adrenal glands.• Beta endorphins are derived from the same precursors as ACTH and are co-secreted withit. The role of endorphins in counterregulation is uncertain, but they may influence thesecretion of the other pituitary hormones during hypoglycaemia.• GH: Growth hormone secretion is governed by two hypothalamic hormones: growthhormone releasing hormone (GHRH) which stimulates GH secretion, and somatostatinwhich is inhibitory. GHRH secretion is stimulated by dopamine, GABA, opiates andthrough alpha adrenoceptors, whereas it is inhibited by serotonin and beta adrenoceptors.A study in rats showed that bioassayable GH and GHRH are depleted in the pituitary andhypothalamus respectively after insulin-induced hypoglycaemia (Katz et al., 1967).• Prolactin: The mechanisms underlying its secretion are not established. Prolactin secre-tion is normally under the inhibitory control of dopamine, but evidence also exists forreleasing factors being produced during hypoglycaemia. Prolactin does not contribute tocounterregulation.Posterior pituitaryVasopressin and oxytocin both increase during hypoglycaemia (Fisher et al., 1987). Theirsecretion is under hormonal and neurotransmitter control in a similar way to the hypothalamic
  25. 25. PHYSIOLOGICAL RESPONSES 15hormones. Vasopressin has glycolytic actions and oxytocin increases hepatic glucose outputin dogs, but their contribution to glucose counterregulation is uncertain.Pancreas• Glucagon: The mechanisms of glucagon secretion during hypoglycaemia are still not fullyunderstood. Although activation of the autonomic nervous system stimulates its release,this pathway has been shown to be less important in humans. A reduction in glucoseconcentrations may have a direct effect on the glucagon-secreting pancreatic alpha cells,or the reduced beta cell activity (reduced insulin secretion), which also occurs with lowblood glucose, may release the tonic inhibition of glucagon secretion. However, suchmechanisms would be disturbed in type 1 diabetes, where hypoglycaemia is normallyassociated with high plasma insulin levels and there is no direct effect of beta cell-derivedinsulin on the alpha cells.• Somatostatin: This is thought of as a pancreatic hormone produced from D cells of theislets of Langerhans, but it is also secreted in other parts of the gastrointestinal tract. Thereare a number of structurally different polypeptides derived from prosomatostatin: thesomatostatin-14 peptide is secreted from D cells, and somatostatin-28 from the gastroin-testinal tract. The plasma concentration of somatostatin-28 increases during hypoglycaemia(Francis and Ensinck, 1987). The normal action of somatostatin is to inhibit the secretionboth of insulin and glucagon, but somatostatin-28 inhibits insulin ten times more effec-tively than glucagon, and thus may have a role in counterregulation by suppressing insulinrelease.• Pancreatic polypeptide: This peptide has no known role in counterregulation, but its releaseduring hypoglycaemia is stimulated by cholinergic fibres through muscarinic receptorsand is a useful marker of parasympathetic activity.Adrenal and Renin–Angiotensin systemThe processes governing the increase in cortisol during hypoglycaemia are discussed above.The rise in catecholamines, in particular epinephrine from the adrenal medulla, which occurswhen blood glucose is lowered, is controlled by sympathetic fibres in the splanchnic nerve.The increase in renin, and therefore angiotensin and aldosterone, during hypoglycaemia isstimulated primarily by the intra-renal effects of increased catecholamines, mediated throughbeta adrenoceptors, although the increase in ACTH and hypokalaemia due to hypoglycaemiacontributes (Trovati et al., 1988; Jungman et al., 1989). These changes do not have asignificant role in counterregulation, although angiotensin II has glycolytic actions in vitro.PHYSIOLOGICAL RESPONSESHaemodynamic Changes (Box 1.4)The haemodynamic changes during hypoglycaemia (Hilsted, 1993) are mostly caused bythe activation of the sympathetic nervous system and an increase in circulating epinephrine.
  26. 26. 16 NORMAL GLUCOSE METABOLISM AND RESPONSESBox 1.4 Haemodynamic changes↑ Heart rate↑ Systolic blood pressure↑ Cardiac output↓ Peripheral resistance↑ Myocardial contractilityAn increase in heart rate (tachycardia), myocardial contractility and cardiac output occurs,which is mediated through beta1 adrenoceptors, but increasing vagal tone counteracts thiseffect so the increase is transient. Peripheral resistance, estimated from mean arterial pressuredivided by cardiac output, is reduced. A combination of the increase in cardiac output andreduction in peripheral resistance results in an increase in systolic and a decrease in diastolicpressure, i.e. a widening of pulse pressure without a change in mean arterial pressure.Changes in Regional Blood Flow (Box 1.5 and Figure 1.8)• Cerebral blood flow: Early work produced conflicting results, but these studies werein subjects receiving insulin shock therapy, and the varying effects of convulsions andaltered level of consciousness may have influenced the outcome. Subsequent studies haveconsistently shown an increase in cerebral blood flow during hypoglycaemia despite theuse of different methods of measurement (isotopic, single photon emission computedtomography (SPECT) and Doppler ultrasound). In most of the studies blood glucoseconcentration was less than 2 mmol/l before a change was observed. In animals, hypogly-caemia is associated with loss of cerebral autoregulation (the ability of the brain to maintaincerebral blood flow despite variability in cardiac output) through beta adrenoceptor stim-ulation, but the exact mechanisms are unknown (Bryan, 1990; Sieber and Traysman,1992).• Gastrointestinal system: Total splanchnic blood flow (supplying the intestines, liver,spleen and stomach) is increased and splanchnic vascular resistance reduced as assessedby the bromosulphthalein extraction technique (Bearn et al., 1952). Superior mesentericartery blood flow measured using Doppler ultrasound increases during hypoglycaemiadue to beta adrenoceptor stimulation (Braatvedt et al., 1993). Radioisotope scanning hasBox 1.5 Changes in regional blood flow↑ Cerebral flow↑ Total splanchnic flow↓ Splenic flowSkin flow variable (early ↑, late ↓)↑ Muscle flow↓ Renal flow
  27. 27. PHYSIOLOGICAL RESPONSES 17Figure 1.8 Changes in regional blood flow during hypoglycaemiademonstrated a reduction in splenic activity during hypoglycaemia (Fisher et al., 1990),which is thought to be a consequence of alpha adrenoceptor-mediated reduction in bloodflow. These changes would all be expected to increase hepatic blood flow.• Skin: The control of blood flow to the skin is complex and different mechanisms predom-inate in different areas. Studies of the effect of hypoglycaemia on skin blood flow areinconsistent partly because different methods have been used for blood flow measure-ment and induction of hypoglycaemia, as well as differences in the part of the bodystudied. Definitive conclusions are therefore not possible. Studies using the dorsum ofthe foot and the face (cheek and forehead) have consistently shown an initial vasodilata-tion and increase in blood flow followed by later vasoconstriction at a blood glucose of2.5 mmol/l (Maggs et al., 1994). These findings are consistent with the clinical pictureof initial flushing and later pallor, with an early rise in skin blood flow followed by alater fall.• Muscle blood flow: A variety of techniques have been used to study muscle blood flow(including venous occlusion plethysmography, isotopic clearance techniques and the useof thermal conductivity meters). All studies have consistently shown an increase in muscle
  28. 28. 18 NORMAL GLUCOSE METABOLISM AND RESPONSESblood flow during hypoglycaemia irrespective of skin blood flow. This change is mediatedby beta2 adrenoceptors (Abramson et al., 1966; Allwood et al., 1959).• Kidney: Inulin and sodium hippurate clearance can be used to estimate glomerular filtrationrate and renal blood flow respectively. Both decrease during hypoglycaemia (Patrick et al.,1989) and catecholamines and renin are implicated in initiating the changes.The changes in blood flow in various organs, like the haemodynamic changes, are mostlymediated by the activation of the sympathetic nervous system or circulating epinephrine. Themajority either protect against hypoglycaemia or increase substrate delivery to vital organs.The increase in cerebral blood flow increases substrate delivery to the brain. Increasingmuscle flow enhances the release and washout of gluconeogenic precursors. The increase insplanchnic blood flow and reduction in splenic blood flow serve to increase hepatic bloodflow to maximise hepatic glucose production. Meanwhile, blood is diverted away fromorgans such as the kidney and spleen, which are not required in the acute response to themetabolic stress.Functional Changes (Box 1.6)• Sweating: Sweating is mediated by sympathetic cholinergic nerves, although other neuro-transmitters such as vasoactive intestinal peptide and bradykinin may also be involved.The activation of the sympathetic innervation of the skin as described above results inthe sudden onset of sweating. Sweating is one of the first physiological responses tooccur during hypoglycaemia and can be demonstrated within ten minutes of achievinga blood glucose of 2.5 mmol/l (Maggs et al., 1994). It coincides with the onset ofother measures of autonomic activation such as an increase in heart rate and tremor(Figure 1.9).• Tremor: Trembling and shaking are characteristic features of hypoglycaemia and resultfrom an increase in physiological tremor. The rise in cardiac output and vasodilata-tion occurring during hypoglycaemia increase the level of physiological tremor and thisis exacerbated by beta adrenoceptor stimulation associated with increased epinephrineconcentrations (Kerr et al., 1990). Since adrenalectomy does not entirely abolish tremor,other components such as the activation of muscle sympathetic activity must beinvolved.Box 1.6 Functional changes↑ Sweating (sudden onset)↑ Tremor↓ Core temperature↓ Intraocular pressure↑ Jejunal activity↑ Gastric emptying
  29. 29. PHYSIOLOGICAL RESPONSES 19We do not have rights to reproduce thisfigure electronicallyFigure 1.9 Sudden onset of sweating, tremor and increase in heart rate during the induction of hypo-glycaemia. Reproduced from Hypoglycaemia and Diabetes: Clinical and Physiological Aspects (edsB.M. Frier and M. Fisher), © 1993 Edward Arnold, by permission of Edward Arnold (Publishers) Ltd• Temperature: Despite a beta adrenoceptor-mediated increase in metabolic rate, coretemperature falls during hypoglycaemia. The mechanisms by which this occurs dependon whether the environment is warm or cold. In a warm environment, heat is lost becauseof sweating and increased heat conduction from vasodilatation. Hypoglycaemia reducescore temperature by 0 3 C and skin temperature up to 2 C (depending on the part of thebody measured) after 60 minutes (Maggs et al., 1994). Shivering is reduced in the cold,and together with vasodilatation and sweating this causes a substantial reduction in core
  30. 30. 20 NORMAL GLUCOSE METABOLISM AND RESPONSEStemperature (Gale et al., 1983). In rats, mortality was increased in animals whose coretemperature was prevented from falling during hypoglycaemia (Buchanan et al., 1991).In humans there is anecdotal evidence from subjects undergoing insulin shock therapythat those who had a rise in body temperature showed delayed neurological recovery(Ramos et al., 1968). These findings support the hypothesis that the fall in core temper-ature reduces metabolic rate, allowing hypoglycaemia to be better tolerated, and thus thechanges in body temperature are of survival value. The beneficial effects are likely tobe limited, particularly in a cold environment, where the impairment of cerebral func-tion means subjects may not realise they are cold, causing them to be at risk of severehypothermia.• Other functional changes include a reduction in intraocular pressure, greater jejunal butnot gastric motility and inconsistent abnormalities of liver function tests. An increasein gastric emptying occurs during hypoglycaemia (Schvarcz et al., 1995), which maybe protective in that carbohydrate delivery to the intestine is increased, enabling fasterglucose absorption and reversal of hypoglycaemia.CONCLUSIONS• Homeostatic mechanisms exist to maintain glucose concentration within narrow limitsdespite a wide variety of circumstances.• The dependence of the central nervous system on glucose has led to a complex series ofbiochemical, functional and haemodynamic changes aimed at restoring glucose concentra-tions, producing symptoms and protecting the body in general, and central nervous systemin particular, against the effects of a low blood glucose (Figure 1.10).• Many symptoms of hypoglycaemia result from the activation of the autonomic nervoussystem and help to warn the individual that blood glucose is low. This encourages theingestion of carbohydrate, so helping to restore glucose concentrations in addition tocounterregulation.• Faster gastric emptying and the changes in regional blood flow which also occur as aresult of the activation of the autonomic nervous system increase substrate delivery.• The greater cerebral blood flow increases glucose delivery to the brain (although lossof autoregulation is undesirable), and the increased splanchnic flow results in a greaterdelivery of gluconeogenic precursors to the liver.• Activation of the autonomic nervous system also increases sweating, and together with theinhibition of shivering, this predisposes to hypothermia, which may be neuroprotective.ACKNOWLEDGEMENTSWe would like to thank Professor Robert Tattersall for reading the chapter and for his helpfulsuggestions.
  31. 31. REFERENCES 21NORMAL GLUCOSE HOMEOSTASISINSULIN : GLUCAGON RATIO(GH and CORTISOL)COUNTERREGULATIONRESTORE BLOODGLUCOSEADRENALCATECHOLAMINESPITUITARYGLUCAGONSYMPTOMS(Autonomic)SWEATINGHYPOTHERMIAINCREASE SUBSTRATEDELIVERYPROTECTION OFVITAL ORGANSGASTRIC EMPTYINGANDCHANGES IN BLOOD FLOWCEREBRALBLOOD FLOW(eating)HYPOGLYCAEMIADETECTION BY BRAIN GLUCOSE SENSORSExcess InsulinPANCREAS(increased substrateproduction)ACTIVATION OFAUTONOMICNERVOUS SYSTEMBLOOD FLOWSPLANCHNICFigure 1.10 Glucose homeostasis and the correction of hypoglycaemiaREFERENCESAbramson EA, Arky RA, Woeber KA (1966). Effects of propranolol on the hormonal and metabolicresponses to insulin induced hypoglycaemia. Lancet ii: 1386–9.Allwood MJ, Hensel H, Papenberg J (1959). Muscle and skin blood flow in the human forearm duringinsulin hypoglycaemia. Journal of Physiology 147: 269–73.Auer RN, Siesjö BK (1988). Biological differences between ischaemia, hypoglycaemia and epilepsy.Annals of Neurology 24: 699–707.
  32. 32. 22 NORMAL GLUCOSE METABOLISM AND RESPONSESBearn AG, Bulling BH, Sherlock S (1952). The response of the liver to insulin in normal subjects andin diabetes mellitus: hepatic vein catheterisation studies. Clinical Science 11: 151–64.Bell GI, Karyano T, Buse JB, Burant CF, Takeda T, Lin D et al. (1990). Molecular biology ofmammalian glucose transporters. Diabetes Care 13: 198–208.Berne C, Fagius J (1986). Skin sympathetic activity during insulin induced hypoglycaemia.Diabetologia 29: 855–60.Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI (1997). Local ventromedial hypotha-lamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats.Journal of Clinical Investigation 99: 361–5.Boyle PJ, Kempers SE, O’Conner AM, Nagy RJ (1995). Brain glucose uptake and unawarenessof hypoglycemia in patients with insulin-dependent diabetes mellitus. New England Journal ofMedicine 333: 1726–31.Braatvedt GD, Flynn MD, Stanners A, Halliwell M, Corrall RJM (1993). Splanchnic blood flow inman: evidence for mediation via a -adrenergic mechanism. Clinical Science 84: 201–7.Bryan RM (1990). Cerebral blood flow and energy metabolism during stress. American Journal ofPhysiology 259: H269–80.Buchanan TA, Cane P, Eng CC, Sipos GF, Lee C (1991). Hypothermia is critical for survival duringprolonged insulin induced hypoglycemia in rats. Metabolism 40: 330–4.Cahill GF (1971). Physiology of insulin in man. Diabetes 20: 785–99.Cryer PE (1981). Glucose counterregulation in man. Diabetes 30: 261–4.Enoksson S, Caprio SK, Rife F, Shulman GI, Tamborlane WV, Sherwin RS (2003). Defective activationof skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia.Journal of Clinical Endocrinology and Metabolism 88: 1503–11.Evans ML, McCrimmon RJ, Flanagan DE, Keshavarz T, Fan X, McNay EC et al. (2004). HypothalamicATP-sensitive K+channels play a key role in sensing hypoglycemia and triggering counterregulatoryepinephrine and glucagon responses. Diabetes 53: 2542–51.Fagius J, Niklasson F, Berne C (1986). Sympathetic outflow in human muscle nerves increases duringhypoglycemia. Diabetes 35: 1124–9.Fagius J, Berne C (1989). Changes in sympathetic nerve activity induced by 2-deoxy-D-glucoseinfusion in humans. American Journal of Endocrinology 256: E714–21.Fish HR, Chernow B, O’Brian JT (1986). Endocrine and neurophysiologic responses of the pituitaryof insulin-induced hypoglycemia: a review. Metabolism 35: 763–80.Fisher M, Baylis PH, Frier BM (1987). Plasma oxytocin, arginine vasopressin and atrial natri-uretic peptide response to insulin-induced hypoglycaemia in man. Clinical Endocrinology 26:179–85.Fisher M, Gillen G, Hepburn DA, Dargie HJ, Barnett E, Frier BM (1990). Splenic responses to acuteinsulin-induced hypoglycaemia in humans. Clinical Science 78: 469–74.Francis BH, Ensinck JW (1987). Differential alterations of the circulating prosomatostatin-derivedpeptides during insulin induced hypoglycemia in man. Journal of Clinical Endocrinology andMetabolism 65: 880–4.Gale EAM, Bennet J, Macdonald IA, Holst JJ, Mathews JA (1983). The physiological effects ofinsulin-induced hypoglycaemia in man: responses at differing levels of blood glucose. ClinicalScience 65: 262–71.Galassetti P, Neill AR, Tate D, Ertl AC, Wasserman DH, Davis SN (2001). Sexual dimorphism in coun-terregulatory responses to hypoglycemia after antecedent exercise. Journal of Clinical Endocrinologyand Metabolism 86: 3516–24.Garber AJ, Cryer PE, Santiago JV, Hammond MW, Pagliara AS, Kipnis DM (1976). The role ofadrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia inman. Journal of Clinical Investigation 58: 7–15.Gerich JE (1988). Glucose counterregulation and its impact in diabetes mellitus. Diabetes 37:1608–17.
  33. 33. REFERENCES 23Hamilton-Wessler M, Bergman RN, Halter JB, Watanabe RM, Donovan CM (1994). The role ofliver glucosensors in the integrated sympathetic response induced by deep hypoglycemia in dogs.Diabetes 43: 1052–60.Heller SR, Macdonald IA (1996). The measurement of cognitive function during acute hypoglycaemia:experimental limitations and their effect on the study of hypoglycaemia unawareness. DiabeticMedicine 13: 607–15.Heptulla RA, Tamborlane WV, Ma TY-Z, Rife F, Sherwin RS (2001). Oral glucose augments thecounterregulatory hormone response during insulin-induced hypoglycemia in humans. Journal ofClinical Endocrinology and Metabolism 86: 645–8.Hilsted J (1993). Cardiovascular changes during hypoglycaemia. Clinical Physiology 13: 1–10.Jackson PA, Cardin S, Coffey CS, Neal DW, Allen EJ, Penazola AR et al. (2000). Effect of hepaticdenervation on the counterregulatory response to insulin-induced hypoglycemia in the dog. AmericanJournal of Endocrinology 279: E1249–57.Jungman E, Konzog C, Holl E, Fassibinder W, Schoffling K (1989). Effect of a human atrial natureticpeptide on blood glucose concentrations and hormone stimulation during insulin-induced hypogly-caemia in healthy man. European Journal of Clinical Pharmacology 36: 593–7.Katz SH, Dhariwal APS, McCann SM (1967). Effects of hypoglycaemia on the content of pituitarygrowth hormone (GH) and hypothalamic growth hormone releasing factor (GNRH) in the rat.Endocrinology 81: 333–9.Kerr D, Macdonald IA, Tattersall RB (1989). Influence of duration of hypoglycemia on the hormonalcounterregulatory response in normal subjects. Journal of Clinical Endocrinology and Metabolism68: 118–22.Kerr D, Macdonald IA, Heller SR, Tattersall RB (1990). A randomised double-blind placebo controlledtrial of the effects of Metoprolol CR, Atenolol and Propranolol LA on the physiological responsesto hypoglycaemia in the non-diabetic. British Journal of Clinical Pharmacology 29: 685–94.Levin BE, Routh VH, Kang L, Sanders NM, Dunn-Meynell AA (2004). Neuronal glucosensing: Whatdo we know after 50 years? Diabetes 53: 2521–8.Maggs DG, Scott AR, Macdonald IA (1994). Thermoregulatory responses to hyperinsulinemic hypo-glycemia and euglycemia in humans. American Journal of Physiology 267: R1266–72.McCall AL, Fixman LB, Fleming N, Tornheim K, Chick W, Ruderman ND (1986). Chronic hypo-glycemia increases brain glucose transport. American Journal of Endocrinology 251: E442–5.McCall AL (1993). Effects of glucose deprivation on glucose metabolism in the central nervous system.In: Hypoglycaemia and Diabetes: Clinical and Physiological Aspects. Frier BM and Fisher M,eds. Edward Arnold, London: 56–71.Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I et al. (1991). Hierarchy of glycemicthresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction. AmericanJournal of Endocrinology 266: E67–74.Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrara MG, Cahill GF Jr (1967). Brain metabolismduring fasting. Journal of Clinical Investigation 46: 1589–95.Patrick AW, Hepburn DA, Craig KJ, Thompson I, Swainson CD, Frier BM (1989). The effects of acuteinsulin-induced hypoglycaemia on renal function in normal human subjects. Diabetic Medicine 6:703–8.Ramos E, Zorilla E, Hadley WB (1968). Fever as a manifestation of hypoglycemia. Journal of theAmerican Medical Association 205: 590–2.Schvarcz E, Palmér M, Åman J, Berne C (1995). Hypoglycemia increases the gastric emptying ratein healthy subjects. Diabetes Care 18: 674–6.Sieber FE, Traysman RJ (1992). Special Issues: Glucose and the brain. Critical Care Medicine 20:104–14.Siegal AM, Kreisberg RA (1975). Metabolic homeostasis: insulin-glucagon interactions. In: DiabetesMellitus (4th edition). Sussman KE and Metz RJS, eds. American Diabetes Association, New York:29–35.
  34. 34. 24 NORMAL GLUCOSE METABOLISM AND RESPONSESSokaloff (1989). Circulation and energy metabolism of the brain. In: Basic Neurochemistry. Siegel G,Agranoff B, Albers RW and Molinoff P, eds. Raven Press, New York: 565–90.Trovati M, Massucco P, Mularoni E, Cavalot F, Anfossi G, Matiello L, Emanuelli G (1988). Insulin-induced hypoglycaemia increases plasma concentrations of angiotensin II and does not modify atrialnaturetic polypeptide secretion in man. Diabetologia 31: 816–20Wieloch T (1985). Hypoglycemia induced neuronal damage prevented by an N-Methyl D-Aspartateantagonist. Science 230: 681–3.
  35. 35. 2 Symptoms of Hypoglycaemiaand Effects on MentalPerformance and EmotionsIan J. DearyINTRODUCTIONThis chapter describes the symptoms that are perceived during acute hypoglycaemia, andthe changes in mental functions and emotions that occur during this metabolic state.The most obvious benefit to a person of knowing about the symptoms of hypoglycaemiais the ability to recognise the onset of a hypoglycaemic episode as early as possible. This isof key importance in informing and educating people with diabetes. Moreover, if a personwith diabetes understands which mental functions are affected by hypoglycaemia he or shecan judge which activities may be most threatened in this state.SYMPTOMS OF HYPOGLYCAEMIAIdentifying the SymptomsThe physiological responses to hypoglycaemia are described in Chapter 1. The responseto hypoglycaemia results in physical symptoms, which raises several questions (McAulayet al., 2001b). Can we compile a comprehensive list of symptoms of hypoglycaemia? Whichare the more common symptoms of hypoglycaemia? Are there early warning symptoms ofhypoglycaemia? Do people differ in how quickly and accurately they detect or recognisehypoglycaemia? Do people differ in the set of symptoms of hypoglycaemia they experience?How can individuals distinguish the symptoms of hypoglycaemia from other bodily changes?The total symptom complexThe most basic question is: what symptoms do people report when they develophypoglycaemia?In humans the symptoms associated with hypoglycaemia were first recorded when insulinbecame available for the treatment of diabetes (Fletcher and Campbell, 1922). A list ofcharacteristic symptoms was described (Table 2.1). It was noted: that some symptomsHypoglycaemia in Clinical Diabetes, 2nd Edition. Edited by B.M. Frier and M. Fisher© 2007 John Wiley & Sons, Ltd
  36. 36. Table2.1CommonsymptomsassociatedwithhypoglycaemiaSymptomsassociatedwithhypoglycaemiaasderivedfrompopulationstudies(afterHepburn,1993)Percentage(minimum–maximum)ofpeoplereportingthegivensymptomasassociatedwithhypoglycaemia(afterHepburn,1993)SymptomsofhypoglycaemiaasnotedbyFletcherandCampbell(1922)Symptoms(andpercentage[tonearest5%])ofpeopleendorsingsymptomsasassociatedwithhypoglycaemia;afterCoxetal.,1993a,Figure2)Sweating47–84SweatingSweating(80)Trembling32–78TremulousnessTrembling(65)Weakness28–71WeaknessFatigue/weak(70)Visualdisturbance24–60DiplopiaBlurredvision(20)Hunger39–49ExcessivehungerHunger(60)Poundingheart8–62ChangeinpulseratePoundingheart(55)Difficultywithspeaking7–41Dysarthria,sensoryandmotoraphasiaSlurredspeech(40)Tinglingaroundthemouth10–39–Numblips(50)Dizziness11–41Vertigo,faintness,syncopeLight-headed/dizzy(60)Headache24–36Headache(30)Anxiety10–44Nervousness,anxiety,excitement,emotionalupsetNervous/tense(65)Nausea5–20––Difficultyconcentrating31–75–Difficultyconcentrating(80)Tiredness38–46–Drowsiness16–33–Drowsy–sleepy(40)Confusion13–53Confusion,disorientation,‘goneness’PallorIncoordinationUncoordinated(75)FeelingofheatorcoldColdsweats(40)EmotionalinstabilitySlowedthinking(70)
  37. 37. SYMPTOMS OF HYPOGLYCAEMIA 27appeared before others during hypoglycaemia; that the blood glucose level at which subjectsbecame aware of hypoglycaemia was characteristic for the individual; that there were largeindividual differences in the levels of blood glucose at which awareness of hypoglycaemiacommenced; and that the preceding blood glucose concentration could affect the onset ofsymptoms.Lists of common symptoms of hypoglycaemia have been compiled from more recentresearch. Hepburn (1993) summarised eight population studies of the symptoms ofhypoglycaemia experienced by adults and children with insulin-treated diabetes, and Coxet al. (1993a) also produced a list of symptoms (Table 2.1). It is evident that the three listsof symptoms do not differ greatly, and that Fletcher and Campbell’s early report (1922)had captured many of the symptoms found in subsequent, more structured investigations.However, their report omitted to mention some symptoms such as tiredness, drowsiness anddifficulty concentrating, though it did include others – such as pallor (a sign rather thana symptom), incoordination and feelings of temperature change – that are emphasised byother researchers as regularly perceived symptoms. Table 2.1 establishes a useful group ofsymptoms that are commonly reported in hypoglycaemia.The way we ask people to describe their symptoms of hypoglycaemia can alter what theytell us. The rank order of symptoms alters considerably if patients are asked to indicate therelevance of each symptom rather than merely to identify that the symptom is associatedwith hypoglycaemia (Cox et al., 1993a). With regard to the criterion of relevance, the mostuseful symptoms in detecting hypoglycaemia are as follows:• sweating;• trembling;• difficulty concentrating;• nervousness, tenseness;• light-headedness, dizziness.The initial symptomsAnother important question is: which hypoglycaemic symptoms appear early during anepisode? The symptoms of hypoglycaemia that appear first and offer early warning of theonset of hypoglycaemia (Hepburn, 1993) are as follows:• trembling;• sweating;• tiredness;• difficulty concentrating;• hunger.This knowledge is obviously useful for the prompt detection and treatment of hypoglycaemia.
  38. 38. 28 SYMPTOMS OF HYPOGLYCAEMIAThe Validity of Symptom BeliefsThe individuality of hypoglycaemic symptom clustersA great deal of the interest in symptoms of hypoglycaemia has been stimulated by concernsabout patient education. It is helpful to let patients know the range of symptoms found inhypoglycaemia and to inform them of the early warning symptoms reported by other peoplewith diabetes, much as we all tend to know the range of symptoms that are experiencedwith the common cold. Many surveys and laboratory studies have shown that people differconsiderably in the symptoms of hypoglycaemia they experience (Cox et al., 1993a). Inaddition to learning the generally reported symptoms, individuals with diabetes should beencouraged to learn about their own typical symptoms of hypoglycaemia.Correctly interpreting symptoms as representing hypoglycaemiaSymptoms of hypoglycaemia do not appear on top of the bodily equivalent of a blank sheetof paper. Sometimes we experience symptoms when there is nothing wrong with our bodilyfunctions; on the other hand, sometimes we fail to notice any symptoms when the body ismalfunctioning. The alert person with diabetes who is on the lookout for hypoglycaemiamust make two sorts of decisions. First, symptoms of hypoglycaemia must be detected andcorrectly identified. It would be dangerous for a patient to ignore symptoms of hypoglycaemiabecause he or she thought they were related to something else. Second, symptoms that havenothing to do with hypoglycaemia must be excluded. Unwanted hyperglycaemia could occurif patients treated themselves for hypoglycaemia when the symptoms had another cause.These two main types of error are a failure to treat hypoglycaemia when blood glucose islow, and inappropriate treatment when blood glucose is acceptable or high (Cox et al., 1985;1993a) (Figure 2.1).Blood glucose concentration – symptom report correlationsDo patients’ reports of symptoms of hypoglycaemia bear any relation to their concur-rent blood glucose concentrations? After all, the principal aim of educating people to beFigure 2.1 Consequences of correct and incorrect perception of hypoglycaemic symptoms
  39. 39. SYMPTOMS OF HYPOGLYCAEMIA 29aware of symptoms of hypoglycaemia is that they become alert to low and potentiallydangerous levels of blood glucose. To answer the above question some researchers haveemployed a field study approach where people are invited to list any symptoms they areexperiencing, and then measure and record their blood glucose concentration several timesa day for weeks. As a result of these studies it is known that each person has somesymptoms that are most reliably associated with their actual blood glucose concentrations(Pennebaker et al., 1981). Some of the symptoms that people report during hypoglycaemiaare more closely related to their actual blood glucose concentrations than are others, and ifwe can identify each individual’s most informative symptoms, we can instruct people to paymore attention to them.The following symptoms are most consistently associated with actual blood glucoseconcentrations (Pennebaker et al., 1981):• hunger (in 53% of people);• trembling (in 33%);• weakness (in 27%);• light-headedness (in 20%);• pounding heart and fast heart rate (both 17%).The same symptoms are not informative for everyone. There were 27% of people for whomweakness was significantly associated with hypoglycaemia, but there were 7% in whom itwas a good symptom of hyperglycaemia! Most people reported more than three symptomsthat were strongly associated with the measured blood glucose concentration.It is evident that an individual’s symptoms are idiosyncratic. If we can help a patientto identify the symptoms of hypoglycaemia peculiar to him or her, which relate toactual blood glucose concentrations, then, by attending to these symptoms, the personshould be especially accurate in recognising hypoglycaemia. People who have one ormore reliable symptom(s) of hypoglycaemia correctly recognise half of their episodes ofhypoglycaemia (defined as a blood glucose less than 3.95 mmol/l [Cox et al., 1993a]).Those who have four or more reliable symptoms recognise a blood glucose below3.95 mmol/l three-quarters of the time. The field study method has suggested that attentionto the following symptoms was particularly useful in detecting actual low blood glucoseconcentrations:• nervousness/tenseness;• slowed thinking;• trembling;• light-headedness/dizziness;• difficulty concentrating;• pounding heart;• lack of co-ordination.
  40. 40. 30 SYMPTOMS OF HYPOGLYCAEMIAClassifying Symptoms of HypoglycaemiaUntil now the symptoms of hypoglycaemia have been treated as a homogeneous whole. Canthese symptoms be divided into different groups?Hypoglycaemia has effects on more than one part of the body, and the symptoms ofhypoglycaemia reflect this. First, the direct effects of a low blood glucose concentrationon the brain – especially the cerebral cortex – cause neuroglycopenic symptoms. Second,autonomic symptoms result from activation of parts of the autonomic nervous system.Finally, there may be some non-specific symptoms that are not directly generated by eitherof these two mechanisms. It is only recently that scientific investigations have taken placeto confirm the idea that these separable groups of hypoglycaemic symptoms exist.As suggested above, there are at least two distinct groups of symptoms during the body’sreaction to hypoglycaemia (Hepburn et al., 1991):• Autonomic, with symptoms such as trembling, anxiety, sweating and warmness.• Neuroglycopenic, with symptoms such as drowsiness, confusion, tiredness, inability toconcentrate and difficulty speaking.This information can assist with patient education by supplying evidence for separablegroups of symptoms, and by indicating which symptoms belong to each group. Someneuroglycopenic symptoms, such as the inability to concentrate, weakness and drowsi-ness, are among the earliest detectable symptoms, but patients tend to rely more on auto-nomic symptoms when detecting the onset of hypoglycaemia. Paying more attention to thepotentially useful, early neuroglycopenic symptoms could help with the early detection ofhypoglycaemia.Similar groups of symptoms of hypoglycaemia have been discovered by asking people torecall the symptoms they typically noticed during hypoglycaemia. However, in addition tothe two groups described above, a general feeling of malaise is added (Deary et al., 1993):• Autonomic: e.g. sweating, palpitations, shaking and hunger.• Neuroglycopenic: e.g. confusion, drowsiness, odd behaviour, speech difficulty andincoordination.• General malaise: e.g. headache and nausea.These 11 symptoms are so reliably reported by people and so clearly separable into thesethree groups, that they are used as the ‘Edinburgh Hypoglycaemia Scale’ (Deary et al.,1993). Table 2.2 shows how different researchers have found similar groups of autonomicand hypoglycaemic symptoms.In addition to the above studies that used patients’ self-reported symptoms, physiologicalstudies have also confirmed that the symptoms of hypoglycaemia can be divided into auto-nomic and neuroglycopenic groups. Symptoms such as sweating, hunger, pounding heart,tingling, nervousness and feeling shaky/tremulous (autonomic symptoms) can be reduced oreven prevented by drugs that block neurotransmission within the autonomic nervous system(Towler et al., 1993), confirming that these symptoms are caused by the autonomic responseto hypoglycaemia. Symptoms such as warmth, weakness, difficulty thinking/confusion,
  41. 41. SYMPTOMS OF HYPOGLYCAEMIA 31Table 2.2 Different authors’ lists of autonomic and neuroglycopenic symptoms of hypoglycaemiaAutonomic NeuroglycopenicDeary et al.(1993)Towler et al.(1993)Weinger et al.(1995)Deary et al.(1993)Towler et al. (1993)Sweating Sweaty Sweating Confusion Difficulty thinking/confusedPalpitation Heart pounding Pounding heart,fast pulseDrowsiness Tired/drowsyShaking Shaky/tremulous Trembling OddbehaviourHunger Hungry SpeechdifficultyDifficulty speakingTingling IncoordinationNervous/anxious Tense WeakBreathing hard Warmfeeling tired/drowsy, feeling faint, difficulty speaking, dizziness and blurred vision (neuro-glycopenic symptoms) are not prevented by drugs that block the autonomic nervous system.Therefore, neuroglycopenic symptoms are not mediated via the autonomic nervous systemand are thought to be caused by the direct effect of glucose deprivation on the brain. Thistype of research has also observed that people tend to rely on autonomic symptoms to detecthypoglycaemia, even when neuroglycopenic symptoms are just as prominent (Towler et al.,1993). Once more, this suggests that more emphasis should be placed on education of thepotential importance of neuroglycopenic symptoms for the early warning of hypoglycaemia.Symptoms might gather into slightly different groupings depending on the situation. Thesymptom groupings in the Edinburgh Hypoglycaemia Scale were developed from diabeticpatients’ retrospective reports. However, when people are asked to rate the same group ofsymptoms during acute, experimentally-induced moderate hypoglycaemia, a slightly differentpattern emerges (McCrimmon et al., 2003). In Table 2.3 there is an autonomic grouping, andthe single neuroglycopenia group has divided into two symptom groups: one with mostlycognitive symptoms and the other with more general symptoms. This division probably arosebecause the subjects in the studies used to form Table 2.3 were engaged in cognitive tasksTable 2.3 Symptom groupings of the Edinburgh Hypoglycaemia Scaleduring experimentally-induced hypoglycaemiaNeuroglycopenic symptomsCognitive dysfunction Neuroglycopenia Autonomic symptomsInability to concentrate Drowsiness SweatingBlurred vision Tiredness TremblingAnxiety Hunger WarmnessConfusion WeaknessDifficulty speakingDouble vision
  42. 42. 32 SYMPTOMS OF HYPOGLYCAEMIAduring the period of hypoglycaemia. Therefore, they would be especially aware of cognitiveshortcomings, making this group of symptoms more prominent and coherent.Symptoms in Children and Older PeopleChildren often have difficulty in recognising symptoms of hypoglycaemia, and they showmarked variability in symptoms between episodes of hypoglycaemia (Macfarlane and Smith,1988). Trembling and sweating are often the first symptoms recognised by children. Frominterviews with the parents of children (aged up to 16 years) with type 1 diabetes, andwith some of their children, more is known about the frequency of symptoms of hypo-glycaemia in children (McCrimmon et al., 1995; Ross et al., 1998) (Table 2.4). The mostfrequently reported sign that parents observed was pallor (noted by 88%). The parentsTable 2.4 Symptoms of hypoglycaemia in children (derived from Ross et al., 1998)Frequency of rating (%) Correlation betweenparents’ and children’sintensity ratingsaSymptom Parents’ reports Children’s reportsTearful 73 47 0 40dHeadache 73 65 0 33dIrritable 85 65 0 16Uncoordinated 62 56 0 18Naughty 47 31 0 23bWeak 79 83 0 21bAggressive 75 62 0 26cTrembling 79 88 0 25bSleepiness 63 69 0 27cNightmares 33 19 0 33dSweating 76 73 0 28cSlurred speech 53 45 0 28cBlurred vision 52 55 0 30cTummy pain 67 41 0 36dFeeling sick 63 53 0 32cHungry 74 84 0 19Yawning 48 45 0 20bOdd behaviour 65 50 0 22bWarmness 57 68 0 13Restless 61 57 0 21bDaydreaming 70 48 0 14Argumentative 64 50 0 21bPounding heart 21 44 0 02Confused 75 70 0 41dTingling lips 20 24 −0 01Dizziness 66 87 0 28cTired 83 76 0 26cFeeling awful 92 79 0 20aCorrelations: p of z (corrected for ties) 1.0 represents perfect agreement; 0 represents no agreement.bp < 0 05, cp < 0 01, dp < 0 001.
  43. 43. SYMPTOMS OF HYPOGLYCAEMIA 33frequently reported symptoms of behavioural disturbance such as irritability, argumentative-ness and aggression. This latter group of symptoms is not prominent in adults, althoughthe Edinburgh Hypoglycaemia Scale includes ‘odd behaviour’ as an adult neuroglycopenicsymptom. Others had previously noted the prominence of symptoms such as irritability,aggression and disobedience in the parents’ reports of their children’s symptoms of hypogly-caemia (Macfarlane and Smith, 1988; Macfarlane et al., 1989). Parents tend to under-reportthe subjective symptoms of hypoglycaemia, such as weakness and dizziness, but gener-ally there is good agreement between parents and their children about the most prominentsymptoms of childhood hypoglycaemia (McCrimmon et al., 1995; Ross et al., 1998).Separate groups of autonomic and neuroglycopenic symptoms were not found in childrenwith type 1 diabetes (McCrimmon et al., 1995; Ross et al., 1998). These symptoms arereported together by children and are not distinguished as separate groups, whereas the groupof symptoms related to behavioural disturbance is clearly reported as a distinct group. In arefinement of the earlier study by McCrimmon et al. (1995), Ross et al. (1998) found thatparents could distinguish between autonomic and neuroglycopenic symptoms.People with insulin-treated type 2 diabetes report symptoms during hypoglycaemia thatseparate into autonomic and neuroglycopenic groups (Henderson et al., 2003). Elderlypatients with type 2 diabetes treated with insulin commonly report neurological symptomsof hypoglycaemia which may be misinterpreted as features of cerebrovascular disease, suchas transient ischaemic attacks (Jaap et al., 1998). The age-specific differences in the groupsof hypoglycaemic symptoms, classified using statistical techniques (Principal ComponentAnalysis), are shown in Table 2.5. Health professionals and carers who are involved inthe treatment and education of diabetic patients should be aware of which symptoms arecommon at either end of the age spectrum.From Symptom Perception to ActionPeople with diabetes are better at estimating their blood glucose in natural, everyday situ-ations, as opposed to clinical laboratory settings (Cox et al., 1985). In some ways this issurprising as natural hypoglycaemia often occurs at a time when it is unexpected. In this situ-ation, attention toward symptoms will not be as actively directed toward detection as in thelaboratory setting where it is usually anticipated. Furthermore, hypoglycaemia in everydaylife occurs on the background of other bodily feelings and must be separated from othercauses of the same symptoms. For example, exercise and various acute illnesses can provokesweating in people with diabetes, independently of their association with hypoglycaemia.In a real-life situation a person must detect symptoms of hypoglycaemia and then interpretthem. Failure to detect symptoms can lead to a failure to treat hypoglycaemia, but detectionTable 2.5 Classification of symptoms of hypoglycaemia using Principal Components Analysis inpatients with insulin-treated diabetes depending on age groupChildren (pre pubertal) Adults ElderlyAutonomic/neuroglycopenic Autonomic AutonomicNeuroglycopenic NeuroglycopenicBehavioural Non-specific malaise Neurological
  44. 44. 34 SYMPTOMS OF HYPOGLYCAEMIAwithout the correct interpretation of the cause of the symptoms is equally dangerous. Further-more, it is obvious that someone who does interpret symptoms correctly as being causedby hypoglycaemia, but who does not take action to treat the low blood glucose, will be atthe same risk. These and other steps toward the avoidance of severe hypoglycaemia demon-strate the key role of education about symptoms in people with diabetes (Gonder-Fredericket al., 1997). The psycho-educational programmes of Blood Glucose Awareness Training(BGAT; Schachinger et al., 2005) and Hypoglycemia Anticipation, Awareness and Treat-ment Training (HAATT; Cox et al., 2004) have led to better recognition of hypoglycaemicstates and reduced frequency of hypoglycaemia.Symptom generationFigure 2.2 outlines the stages that intervene between low blood glucose occurring in anindividual and the implementation of effective treatment (Gonder-Frederick et al., 1997). Itis interesting to note the importance of behavioural factors in generating states of low bloodglucose. Episodes of low blood glucose are most likely to come about because of changesin routine aspects of diabetes management, such as taking extra insulin, eating less food ortaking more exercise (Clarke et al., 1997). These factors predict more than 85% of episodesof hypoglycaemia in people with diabetes.In the presence of an intact physiological response to low blood glucose, autonomic andneuroglycopenic symptoms, and symptoms of general malaise, are generated (Figure 2.2).The degree of hypoglycaemia, the person’s quality of glycaemic control and any recentepisodes of hypoglycaemia may all affect the magnitude of the body’s physiological response.Recent, preceding hypoglycaemia can reduce the symptomatic and counterregulatoryhormonal responses to subsequent hypoglycaemia, resulting in a diminished awareness ofsymptoms. This effect of ‘antecedent’ hypoglycaemia is described in Chapter 7. Gender doesnot appear to influence the symptomatic response to hypoglycaemia (Geddes et al., 2006).At the second stage in Figure 2.2 comes the actual generation of physical symptoms.Among the variables that can influence this stage is the prior ingestion of caffeine, whichhas been shown to enhance the intensity of the autonomic and neuroglycopenic symptomsof experimentally induced hypoglycaemia (Debrah et al., 1996) (see Chapter 5). Caffeinemay act by increasing the intensity of symptoms of hypoglycaemia to perceptible levels,much as a magnifying glass enables one to read otherwise too-small print.Symptom detectionThe occurrence of physiological changes in the body does not guarantee that a personwill detect symptoms (Gonder-Frederick et al., 1997). If attention is directed to physicalchanges, people are more likely to detect symptoms than if their attention is held elsewhere.Everyone has had the experience of feeling less discomfort, and being less likely to detecta physical symptom, when being distracted by something diverting. The personal relevanceof the symptom may affect detection; for example, a person with heart disease may be verylikely to detect palpitations (Cox et al., 1993a). The activity of the person at the time ofthe physiological change is obviously important. Hypoglycaemic symptoms will be moreobvious to the person engaged in active mental effort (McCrimmon et al., 2003), such assitting an examination, than to the person relaxing and watching television. A doctor engagedin microsurgery may be very sensitive to the onset of tremor. In one laboratory study the
  45. 45. SYMPTOMS OF HYPOGLYCAEMIA 35Figure 2.2 A model for the occurrence and avoidance of severe hypoglycaemia (after Gonder-Frederick et al., 1997). Note on the right-hand side of each stage the factors that affect its occurrencepeople who had higher anxiety levels were better at detecting symptoms of hypoglycaemia(Ryan et al., 2002).The autonomic symptoms of hypoglycaemia are often emphasised in the detection of hypo-glycaemia. However, a strong case can be made for an equal emphasis on neuroglycopenicsymptoms (Gonder-Frederick et al., 1997; McCrimmon et al., 2003) because:• performance on mental tasks deteriorates during hypoglycaemia, and subjective awarenessof this decrement begins at very mild levels of hypoglycaemia• the difference in glycaemic thresholds for the onset of autonomic and neuroglycopenicsymptoms is so small that it is unlikely to be detected when blood glucose declines rapidly
  46. 46. 36 SYMPTOMS OF HYPOGLYCAEMIA• neuroglycopenic symptoms are as strongly related to actual blood glucose concentrationsas are autonomic symptoms (Cox et al., 1993a)• people with insulin-treated diabetes cite autonomic and neuroglycopenic symptoms withequal frequency as the primary warning symptoms of hypoglycaemia (Hepburn et al., 1991).Low blood glucose detection – symptom interpretationThe correct detection of a symptom of hypoglycaemia does not always lead to correctinterpretation (Figure 2.2). After correctly detecting relevant symptoms, people fail to detectabout 26% of episodes of low blood glucose (Gonder-Frederick et al., 1997). There areseveral factors that could break a perfect relationship between detection and recognition,and some are discussed below. However, it should be appreciated that symptom detection(internal cues) is not mandatory for the detection of low blood glucose. Self-testing of bloodglucose or the information of family members (external cues) can lead to the successfulrecognition of hypoglycaemia without the patient having detected the episode by symptomaticperception (see Box 2.1).Correct knowledge about symptoms of hypoglycaemia is necessary for the detection oflow blood glucose. The lack of such knowledge among elderly people with diabetes inparticular gives cause for concern (Mutch and Dingwall-Fordyce, 1985). Of 161 diabeticpeople between ages 60 and 87, all of whom were injecting insulin or taking a sulphonylurea,only 22% had ever been told the symptoms of hypoglycaemia and 9% knew no symptomsat all! The percentages of the insulin-treated diabetic patients who knew that the followingsymptoms were associated with hypoglycaemia were as follows:• sweating (82%);• palpitations (62%);• confusion (53%);• hunger (51%);• inability to concentrate (50%);• speech problems (41%);• sleepiness (33%).Box 2.1 Identification of hypoglycaemia• Internal cues – autonomic, neuroglycopenic and non-specific symptoms• External cues – relationship of insulin injection to meals, exercise and experienceof self-management• Blood glucose monitoring• Information from observers (e.g. relatives, friends, colleagues)
  47. 47. ACUTE HYPOGLYCAEMIA AND COGNITIVE FUNCTIONING 37In the midst of this ignorance, much hypoglycaemia may not be treated because of a lackof knowledge of the symptoms of hypoglycaemia which would aid their recognition.Most, if not all, of the symptoms of hypoglycaemia can be explained by other physicalconditions. Therefore, correct symptom detection may be usurped by incorrect attribution ofthe cause. For example, having completed some strenuous activity, an athlete may attributethe symptoms of sweating and palpitations to physical exertion. An obvious problem indetecting a low blood glucose is the fact that the organ responsible for the detectionand interpretation of symptoms – the brain, especially the cerebral cortex – is impaired.Thus, impaired concentration and lowered consciousness levels can beget even more severehypoglycaemia.Symptom scoring systemsThe controversy about the effect of human insulin on symptom awareness (Chapter 7)stimulated the development of scoring systems for hypoglycaemia to allow comparativestudies between insulin species. This produced scoring systems such as the EdinburghHypoglycaemia Scale (Deary et al., 1993), and any such system must be validated forresearch application. It is important to note that the nature and intensity of individualsymptoms are as important as, if not more important than, the number of symptoms gener-ated by hypoglycaemia. The concepts involved are discussed in detail by Hepburn (1993).More information on the symptoms of hypoglycaemia is provided by McAulay et al.(2001b).ACUTE HYPOGLYCAEMIA AND COGNITIVE FUNCTIONINGSymptoms are subjective reports of bodily sensations. With respect to hypoglycaemia someof these reports – especially neuroglycopenic symptoms – pertain to altered cognitive(mental ability) functioning. Do reports of ‘confusion’ and ‘difficulty thinking’ (Table 2.2)concur with objective mental test performance in hypoglycaemia? Before experimentalhypoglycaemia became an accepted investigative tool in diabetes, expert clinical observersnoted impairments of cognitive functions despite clear consciousness during hypoglycaemia(Fletcher and Campbell, 1922; Wilder, 1943). Cognitive functions include the following sortsof mental activity: orientation and attention, perception, memory (verbal and non-verbal),language, construction, reasoning, executive function and motor performance. Early studies(Russell and Rix-Trot, 1975) established that the following abilities become disrupted belowblood glucose levels of about 3.0 mmol/l:• fine motor co-ordination;• mental speed;• concentration;• some memory functions.
  48. 48. 38 SYMPTOMS OF HYPOGLYCAEMIAThe hyperinsulinaemic glucose clamp technique allows more controlled experiments ofacute hypo- and hyperglycaemia. However, although this technique is used in most studiesof cognitive function in hypoglycaemia, it does not mimic the physiological or temporalcharacteristics of ‘natural’ or intercurrent episodes of hypoglycaemia experienced by peoplewith type 1 diabetes. From laboratory experiments using the glucose clamp technique it wasfound that blood glucose concentrations between 3.1 and 3.4 mmol/l caused the followingeffects (Holmes, 1987; Deary, 1993):• Slowed reaction times (this experiment involves making a fast response when a lightappears on a computer screen. Hypoglycaemia had more effect on reaction times whenthe reaction involved making a decision).• Slowed mental arithmetic.• Impaired verbal fluency (in this test one has to think of words beginning with a givenletter, probably involving the frontal lobes of the brain).• Impaired performance in parts of the Stroop test (in this test one has to read aloud a seriesof ink colours when words are printed in a different colour from that of the name, e.g. theword RED printed in green ink).Some mental functions were spared during hypoglycaemia, for example:• simple motor (like the speed of tapping) and sensory skills;• the speed of reading words aloud.By 1993 over 16 studies had investigated cognitive functions during acute and mild–moderate hypoglycaemia (Deary, 1993). The levels of blood glucose ranged from 2.0 to3.7 mmol/l. The way that hypoglycaemia was induced varied among studies, as did themethods of blood sampling (e.g. arterialised or venous blood). Moreover, the ability levelsof the people in different studies varied, and there was much heterogeneity in the testbatteries used to assess mental performance. An authoritative statement as to the mentalfunctions disrupted during hypoglycaemia is still not possible. However, in at least one ormore of the studies a number of tests were significantly impaired during hypoglycaemia(Box 2.2).Few areas of mental function are preserved at normal levels during acute hypoglycaemia.There is a general dampening of many abilities that involve conscious mental effort. In theface of so many deleterious effects, what mental functions remain intact during acute hypo-glycaemia? At blood glucose concentrations similar to those indicated above, the followingmental tests are not significantly impaired:• finger tapping;• forward digit span (repeating back a list of numbers in the same order);• simple reaction time;• elementary sensory processing.
  49. 49. ACUTE HYPOGLYCAEMIA AND COGNITIVE FUNCTIONING 39Box 2.2 Cognitive function tests impaired during acute hypoglycaemia• Trail making (involving visual scanning and mental flexibility)• Digit symbol (speed of replacing a list of numbers with abstract codes)• Reaction time (especially involving a decision)• Mental arithmetic• Verbal fluency• Stroop test• Grooved pegboard (a test of fine manual dexterity)• Pursuit rotor (a test of eye–hand co-ordination)• Letter cancellation (striking out occurrences of a given letter in a page of letters)• Delayed verbal memory• Backward digit span (repeating back a list of numbers backwards)• Story recallThus tests which involve speeded responses and which are more cognitively complex andattention-demanding tend to show impairment during hypoglycaemia (Deary, 1993). Hellerand Macdonald (1996) have concluded that:• even quite severe degrees of hypoglycaemia do not impair simple motor functions;• choice reaction time (where a mental decision of some kind is needed before reacting toa stimulus) is affected at higher blood glucose concentrations more than simple reactiontime;• speed of responding is sometimes slowed in a task in which accuracy is preserved;• many aspects of mental performance become impaired when blood glucose falls belowabout 3.0 mmol/l;• there are important individual differences; some people’s mental performance is alreadyimpaired above a blood glucose of 3.0 mmol/l, whereas others continue to function wellat lower levels;• the speed of response of the brain in making decisions slows down during hypoglycaemia(Tallroth et al., 1990; Jones et al., 1990);• it can take as long as 40 to 90 minutes after blood glucose returns to normal for the brainto recover fully (Blackman et al., 1992; Lindgren et al., 1996).

×